Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Rein Therapeutics Q3 2026 Results: Net Loss of $5.54M, Loss Narrows

Rein Therapeutics reported a net loss of $17.8 million for the nine months ended September 30, 2026, compared to $17.9 million in the prior year. The company significantly strengthened its balance sheet through common stock issuances, ending the period with $35.5 million in cash and short-term investments compared to $3.2 million at the end of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-5.5-5.6
EPS (diluted, $ a share)$-0.06$-0.21

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: RNTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Rein Therapeutics, Inc.: key numbers

Share price
$0.4000Close, Nov 16
Market cap
$34.5M
Shares outstanding
86.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Rein Therapeutics, Inc.

All →
8:39 AM ET 8-K
Clinical Trial Data

Rein Therapeutics Clinical Trial Data

Rein Therapeutics announced preliminary blinded Phase 2 data from its RENEW trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). The data showed that 33% of evaluable patients demonstrated improvement in forced vital capacity (FVC) at Week 12, with favorable safety and tolerability observed across the study population.

“As we continue to enroll patients in the study, today’s blinded look at the data shows encouraging lung function trends and a favorable safety and tolerability profile across the study population, reinforcing our confidence in the potential of LTI-03 to deliver a differentiated clinical and safety profile for patients with significant unmet need.”

Brian Windsor, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.